Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
PURPOSE: To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-hour continuous intravenous infusion (CIV). PATIENTS AND METHODS: Forty-seven patients with refractory neoplasms received UCN-01 during this phase I trial. Total, free plasma, and salivary concentrations were determined; the latter were used to address the influence of plasma protein binding on peripheral tissue distribution. The phosphorylation state of the protein kinase C (PKC) substrate alpha-adducin and the abrogation of DNA damage checkpoint also were assessed. RESULTS: The recommended phase II dose of UCN-01 as a 72-hour CIV is 42.5 mg/m 2/d for 3 days. Avid plasma protein binding of UCN-01, as measured during the trial, dictated a change in dose escalation and administration schedules. Therefore, nine patients received drug on the initial 2-week schedule, and 38 received drug on the recommended 4-week schedule. DLTs at 53 mg/m 2/d for 3 days included hyperglycemia with resultant metabolic acidosis, pulmonary dysfunction, nausea, vomiting, and hypotension. Pharmacokinetic determinations at the recommended dose of 42.5 mg/m 2/d for 3 days included mean total plasma concentration of 36.4 μM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h. The mean total salivary concentration was 111 nmol/L of UCN-01. One partial response was observed in a patient with melanoma, and one protracted period ( > 2.5 years) of disease stability was observed in a patient with alk-positive anaplastic large-cell lymphoma. Preliminary evidence suggests UCN-01 modulation of both PKC substrate phosphorylation and the DNA damage-related G 2 checkpoint. CONCLUSION: UCN-01 can be administered safely as an initial 72-hour CIV with subsequent monthly doses administered as 36-hour infusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
(1999) · PubMed · Cited by 1,030
Drug binding to human alpha-1-acid glycoprotein in health and disease.
Kremer, J. M., Wilting, J., & Janssen, L. H. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 583
Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5600 · Cited by 544
Self-citationUCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Self-citation(2000) · PubMed · Cited by 314
Carlson, B., Lahusen, T. J., Singh, S., Loaiza‐Perez, A., Worland, P. J., Pestell, R. G., Albanese, C., Sausville, E. A., & Senderowicz, A. M. (1999) · PubMed · Cited by 287
Self-citationPKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro, D., Ruetz, S., Bodis, S. B., Pruschy, M. N., Csermak, K., Man, A., Campochiaro, P. A., Wood, J. M., O'Reilly, T., & Meyer, T. (2000) · PubMed · Cited by 271
Potent and Specific Inhibitors of Protein Kinase C of Microbial Origin
Tamaoki, T., & Nakano, H. (1990) · Nature Biotechnology · doi:10.1038/nbt0890-732 · Cited by 259
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 229
Self-citation
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Role of cell cycle in mediating sensitivity to radiotherapy
Pawlik, T. M., & Keyomarsi, K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.03.005 · Cited by 1,102
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening
Foloppe, N., Fisher, L. M., Howes, R., Potter, A., Robertson, A. G. S., & Surgenor, A. E. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.03.021 · Cited by 363
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348
Martelli, A. M., Nyåkern, M., Tabellini, G., Bortul, R., Tazzari, P. L., Evangelisti, C., & Cocco, L. (2006) · Leukemia · doi:10.1038/sj.leu.2404245 · Cited by 342
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, C. X., Janetka, J. W., & Piwnica-Worms, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.009 · Cited by 271
Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Metadata
- Authors
- Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., Jing, X.-X., Roberge, M., Fuse, E., Kuwabara, T., & Senderowicz, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-04-15
- Volume
- 19
- Issue
- 8
- Pages
- 2319-2333
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1896635905
- Cited by
- 291
- References
- 33
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.